Advertisement

Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?

Abstract

Malignant pleural mesothelioma is a rare cancer with a cause-effect relationship to asbestos exposure. The prognosis is poor and chemotherapy seems the best treatment option. In the last two decades a deeper understanding of mesothelioma carcinogenesis and invasiveness mechanisms has prompted research efforts to test new agents in patients with malignant pleural mesothelioma, but the results have been modest. Attractive preclinical data disappointed in subsequent experimental phases. Other promising agents failed to improve patient outcomes due to high toxicity. Interesting suggestions have come from preliminary data on immunotherapy. Several trials are ongoing and the results are eagerly awaited. The aim of this review is to discuss the most recent news on systemic therapy for advanced malignant pleural mesothelioma.

Tumori 2016; 102(1): 18 - 30

Article Type: REVIEW

DOI:10.5301/tj.5000436

Authors

Diego Signorelli, Marianna Macerelli, Claudia Proto, Milena Vitali, Maria Silvia Cona, Francesco Agustoni, Nicoletta Zilembo, Marco Platania, Annalisa Trama, Rosaria Gallucci, Monica Ganzinelli, Giuseppe Pelosi, Ugo Pastorino, Filippo de Braud, Marina Chiara Garassino, Giuseppe Lo Russo

Article History

Disclosures

Financial support: None.
Conflict of interest: The authors declare that there are no conflicts of interest associated with this publication.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  • Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan - Italy
  • Department of Preventive and Predictive Medicine, Fondazione IRCSS Istituto Nazionale dei Tumori, Milan - Italy
  • Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan - Italy
  • Division of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan - Italy
  • Diego Signorelli and Marianna Macerelli contributed equally to this work.

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.